Your browser doesn't support javascript.
loading
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
Wheatley, Adam K; Pymm, Phillip; Esterbauer, Robyn; Dietrich, Melanie H; Lee, Wen Shi; Drew, Damien; Kelly, Hannah G; Chan, Li-Jin; Mordant, Francesca L; Black, Katrina A; Adair, Amy; Tan, Hyon-Xhi; Juno, Jennifer A; Wragg, Kathleen M; Amarasena, Thakshila; Lopez, Ester; Selva, Kevin J; Haycroft, Ebene R; Cooney, James P; Venugopal, Hariprasad; Tan, Li Lynn; O Neill, Matthew T; Allison, Cody C; Cromer, Deborah; Davenport, Miles P; Bowen, Richard A; Chung, Amy W; Pellegrini, Marc; Liddament, Mark T; Glukhova, Alisa; Subbarao, Kanta; Kent, Stephen J; Tham, Wai-Hong.
Afiliación
  • Wheatley AK; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; Australian Research Council Centre for Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne, VIC 3010, A
  • Pymm P; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • Esterbauer R; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Dietrich MH; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • Lee WS; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Drew D; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • Kelly HG; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Chan LJ; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • Mordant FL; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Black KA; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • Adair A; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
  • Tan HX; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Juno JA; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Wragg KM; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Amarasena T; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Lopez E; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Selva KJ; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Haycroft ER; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Cooney JP; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • Venugopal H; Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.
  • Tan LL; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
  • O Neill MT; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
  • Allison CC; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • Cromer D; Kirby Institute, University of New South Wales, Kensington, NSW 2052, Australia.
  • Davenport MP; Kirby Institute, University of New South Wales, Kensington, NSW 2052, Australia.
  • Bowen RA; Laboratory of Animal Reproduction and Biotechnology, Colorado State University, Fort Collins, CO 80523, USA.
  • Chung AW; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • Pellegrini M; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3010, Australia.
  • Liddament MT; CSL Limited, Parkville, VIC 3052, Australia.
  • Glukhova A; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3010, Australia; Drug Discovery Biology, Monash Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville VIC 3052,
  • Subbarao K; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street,
  • Kent SJ; Department of Microbiology and Immunology, University of Melbourne, the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia; Australian Research Council Centre for Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne, VIC 3010, A
  • Tham WH; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, VIC 3010, Australia. Electronic address: tham@wehi.edu.au.
Cell Rep ; 37(2): 109822, 2021 10 12.
Article en En | MEDLINE | ID: mdl-34610292
Potent neutralizing monoclonal antibodies are one of the few agents currently available to treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the viral spike protein can exhibit neutralization resistance, potentially affecting the effectiveness of some antibody-based therapeutics. Here, the generation of a diverse panel of 91 human, neutralizing monoclonal antibodies provides an in-depth structural and phenotypic definition of receptor binding domain (RBD) antigenic sites on the viral spike. These RBD antibodies ameliorate SARS-CoV-2 infection in mice and hamster models in a dose-dependent manner and in proportion to in vitro, neutralizing potency. Assessing the effect of mutations in the spike protein on antibody recognition and neutralization highlights both potent single antibodies and stereotypic classes of antibodies that are unaffected by currently circulating VOCs, such as B.1.351 and P.1. These neutralizing monoclonal antibodies and others that bind analogous epitopes represent potentially useful future anti-SARS-CoV-2 therapeutics.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Enzima Convertidora de Angiotensina 2 / SARS-CoV-2 Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Enzima Convertidora de Angiotensina 2 / SARS-CoV-2 Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Cell Rep Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos